nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Irinotecan—colon cancer	0.121	0.212	CbGbCtD
Leflunomide—ABCG2—Fluorouracil—colon cancer	0.116	0.203	CbGbCtD
Leflunomide—ABCG2—Vincristine—colon cancer	0.106	0.185	CbGbCtD
Leflunomide—CYP2C9—Capecitabine—colon cancer	0.0726	0.128	CbGbCtD
Leflunomide—ABCG2—Methotrexate—colon cancer	0.0639	0.112	CbGbCtD
Leflunomide—CYP1A2—Fluorouracil—colon cancer	0.0478	0.0839	CbGbCtD
Leflunomide—CYP2C9—Fluorouracil—colon cancer	0.043	0.0756	CbGbCtD
Leflunomide—PTK2B—embryo—colon cancer	0.00506	0.0816	CbGeAlD
Leflunomide—DHODH—lymphoid tissue—colon cancer	0.00502	0.0809	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—colon cancer	0.00398	0.0641	CbGeAlD
Leflunomide—PTK2B—renal system—colon cancer	0.00383	0.0617	CbGeAlD
Leflunomide—DHODH—liver—colon cancer	0.0037	0.0596	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—colon cancer	0.00327	0.0527	CbGeAlD
Leflunomide—PTK2B—lymphoid tissue—colon cancer	0.00318	0.0513	CbGeAlD
Leflunomide—PTK2B—digestive system—colon cancer	0.00314	0.0506	CbGeAlD
Leflunomide—PTK2B—bone marrow—colon cancer	0.0029	0.0467	CbGeAlD
Leflunomide—DHODH—lymph node—colon cancer	0.00283	0.0457	CbGeAlD
Leflunomide—PTK2B—vagina—colon cancer	0.00278	0.0447	CbGeAlD
Leflunomide—AHR—digestive system—colon cancer	0.00258	0.0416	CbGeAlD
Leflunomide—AHR—bone marrow—colon cancer	0.00238	0.0384	CbGeAlD
Leflunomide—PTK2B—liver—colon cancer	0.00234	0.0377	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—colon cancer	0.00229	1	CrCbGaD
Leflunomide—AHR—vagina—colon cancer	0.00228	0.0368	CbGeAlD
Leflunomide—AHR—liver—colon cancer	0.00193	0.031	CbGeAlD
Leflunomide—PTK2B—lymph node—colon cancer	0.0018	0.0289	CbGeAlD
Leflunomide—AHR—lymph node—colon cancer	0.00148	0.0238	CbGeAlD
Leflunomide—CYP1A2—renal system—colon cancer	0.00118	0.0189	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.00101	0.00654	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000993	0.00641	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000993	0.00641	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—FGFR3—colon cancer	0.00097	0.00626	CbGpPWpGaD
Leflunomide—CYP1A2—digestive system—colon cancer	0.000965	0.0155	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000938	0.00606	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000935	0.00604	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000933	0.00603	CbGpPWpGaD
Leflunomide—ABCG2—bone marrow—colon cancer	0.000924	0.0149	CbGeAlD
Leflunomide—CYP2C9—digestive system—colon cancer	0.000916	0.0148	CbGeAlD
Leflunomide—DHODH—Metabolism—ODC1—colon cancer	0.000909	0.00587	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CHST5—colon cancer	0.000909	0.00587	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—MYC—colon cancer	0.000907	0.00586	CbGpPWpGaD
Leflunomide—ABCG2—vagina—colon cancer	0.000885	0.0143	CbGeAlD
Leflunomide—PTK2B—Alpha-synuclein signaling—SRC—colon cancer	0.000852	0.00551	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TYMS—colon cancer	0.000836	0.0054	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—CDH1—colon cancer	0.00082	0.00529	CbGpPWpGaD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—SRC—colon cancer	0.000811	0.00524	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CHST4—colon cancer	0.000798	0.00515	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000797	0.00515	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—SRC—colon cancer	0.000792	0.00511	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD8A—colon cancer	0.000788	0.00509	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000784	0.00506	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—PPARG—colon cancer	0.000775	0.00501	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TYMS—colon cancer	0.000772	0.00499	CbGpPWpGaD
Leflunomide—ABCG2—liver—colon cancer	0.000747	0.012	CbGeAlD
Leflunomide—CYP1A2—liver—colon cancer	0.000719	0.0116	CbGeAlD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—colon cancer	0.000696	0.0045	CbGpPWpGaD
Leflunomide—CYP2C9—liver—colon cancer	0.000682	0.011	CbGeAlD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.00067	0.00433	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000656	0.00424	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—PIK3CA—colon cancer	0.000648	0.00419	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—AKT1—colon cancer	0.000629	0.00406	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—colon cancer	0.000621	0.00401	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—PIK3CA—colon cancer	0.000602	0.00389	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—colon cancer	0.0006	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—colon cancer	0.000599	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—NRAS—colon cancer	0.000588	0.0038	CbGpPWpGaD
Leflunomide—ABCG2—lymph node—colon cancer	0.000572	0.00922	CbGeAlD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—colon cancer	0.000557	0.0036	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND1—colon cancer	0.000554	0.00358	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CTNNB1—colon cancer	0.000549	0.00354	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—CASP3—colon cancer	0.000548	0.00354	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—PPARG—colon cancer	0.000547	0.00353	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—SRC—colon cancer	0.000547	0.00353	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CTNNB1—colon cancer	0.000546	0.00353	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CASP3—colon cancer	0.000541	0.00349	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CDKN1A—colon cancer	0.000533	0.00344	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—NRAS—colon cancer	0.000526	0.0034	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—KRAS—colon cancer	0.000506	0.00327	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—colon cancer	0.000503	0.00325	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000502	0.00324	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—colon cancer	0.00049	0.00316	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000489	0.00316	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000489	0.00316	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000484	0.00313	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—SRC—colon cancer	0.000483	0.00312	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—SRC—colon cancer	0.000483	0.00312	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—SRC—colon cancer	0.000477	0.00308	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—SRC—colon cancer	0.000471	0.00305	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—colon cancer	0.000471	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—colon cancer	0.000471	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—PIK3CA—colon cancer	0.000465	0.003	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—colon cancer	0.000459	0.00297	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—SRC—colon cancer	0.000455	0.00294	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—KRAS—colon cancer	0.000453	0.00292	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EP300—colon cancer	0.00045	0.00291	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—colon cancer	0.000443	0.00286	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—colon cancer	0.000441	0.00285	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000441	0.00285	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—colon cancer	0.00043	0.00278	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000429	0.00277	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000426	0.00275	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.00042	0.00271	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—colon cancer	0.000418	0.0027	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PIK3CA—colon cancer	0.000416	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—PIK3CA—colon cancer	0.000416	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—colon cancer	0.000416	0.00268	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—APC—colon cancer	0.000406	0.00262	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CDH1—colon cancer	0.000406	0.00262	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000392	0.00253	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—KRAS—colon cancer	0.00039	0.00252	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—colon cancer	0.000385	0.00249	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—SRC—colon cancer	0.000384	0.00248	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000384	0.00248	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—EP300—colon cancer	0.000379	0.00244	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—PIK3CA—colon cancer	0.000368	0.00238	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Capecitabine—colon cancer	0.000367	0.00173	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CHST5—colon cancer	0.000366	0.00237	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Vincristine—colon cancer	0.000366	0.00173	CcSEcCtD
Leflunomide—Stomatitis—Capecitabine—colon cancer	0.000365	0.00173	CcSEcCtD
Leflunomide—Jaundice—Capecitabine—colon cancer	0.000365	0.00173	CcSEcCtD
Leflunomide—Infection—Vincristine—colon cancer	0.000364	0.00172	CcSEcCtD
Leflunomide—Conjunctivitis—Capecitabine—colon cancer	0.000364	0.00172	CcSEcCtD
Leflunomide—Urinary tract infection—Capecitabine—colon cancer	0.000364	0.00172	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000362	0.00234	CbGpPWpGaD
Leflunomide—Osteoarthritis—Methotrexate—colon cancer	0.000361	0.00171	CcSEcCtD
Leflunomide—Nervous system disorder—Vincristine—colon cancer	0.000359	0.0017	CcSEcCtD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000359	0.00232	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—colon cancer	0.000359	0.00232	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Vincristine—colon cancer	0.000358	0.0017	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—EP300—colon cancer	0.000358	0.00231	CbGpPWpGaD
Leflunomide—Haematuria—Capecitabine—colon cancer	0.000357	0.00169	CcSEcCtD
Leflunomide—Anaphylactic shock—Irinotecan—colon cancer	0.000356	0.00169	CcSEcCtD
Leflunomide—Myalgia—Fluorouracil—colon cancer	0.000356	0.00169	CcSEcCtD
Leflunomide—Chest pain—Fluorouracil—colon cancer	0.000356	0.00169	CcSEcCtD
Leflunomide—Infection—Irinotecan—colon cancer	0.000354	0.00168	CcSEcCtD
Leflunomide—Hyperhidrosis—Vincristine—colon cancer	0.000354	0.00167	CcSEcCtD
Leflunomide—Hepatobiliary disease—Capecitabine—colon cancer	0.000354	0.00167	CcSEcCtD
Leflunomide—Epistaxis—Capecitabine—colon cancer	0.000353	0.00167	CcSEcCtD
Leflunomide—Discomfort—Fluorouracil—colon cancer	0.000352	0.00166	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—CTNNB1—colon cancer	0.00035	0.00226	CbGpPWpGaD
Leflunomide—Nervous system disorder—Irinotecan—colon cancer	0.00035	0.00165	CcSEcCtD
Leflunomide—Agranulocytosis—Capecitabine—colon cancer	0.000349	0.00165	CcSEcCtD
Leflunomide—Thrombocytopenia—Irinotecan—colon cancer	0.000349	0.00165	CcSEcCtD
Leflunomide—Anorexia—Vincristine—colon cancer	0.000349	0.00165	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—BRAF—colon cancer	0.000348	0.00225	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—colon cancer	0.000347	0.00224	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—colon cancer	0.000346	0.00223	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—colon cancer	0.000345	0.00223	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Irinotecan—colon cancer	0.000345	0.00163	CcSEcCtD
Leflunomide—Hypotension—Vincristine—colon cancer	0.000342	0.00162	CcSEcCtD
Leflunomide—Anaphylactic shock—Fluorouracil—colon cancer	0.000341	0.00162	CcSEcCtD
Leflunomide—PTK2B—Endothelins—HRAS—colon cancer	0.00034	0.0022	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—colon cancer	0.00034	0.00219	CbGpPWpGaD
Leflunomide—Anorexia—Irinotecan—colon cancer	0.00034	0.00161	CcSEcCtD
Leflunomide—Infection—Fluorouracil—colon cancer	0.000339	0.0016	CcSEcCtD
Leflunomide—Haemoglobin—Capecitabine—colon cancer	0.000338	0.0016	CcSEcCtD
Leflunomide—Rhinitis—Capecitabine—colon cancer	0.000337	0.00159	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—colon cancer	0.000336	0.00217	CbGpPWpGaD
Leflunomide—Haemorrhage—Capecitabine—colon cancer	0.000336	0.00159	CcSEcCtD
Leflunomide—Hepatitis—Capecitabine—colon cancer	0.000336	0.00159	CcSEcCtD
Leflunomide—Nervous system disorder—Fluorouracil—colon cancer	0.000335	0.00158	CcSEcCtD
Leflunomide—Thrombocytopenia—Fluorouracil—colon cancer	0.000334	0.00158	CcSEcCtD
Leflunomide—Liver function test abnormal—Methotrexate—colon cancer	0.000334	0.00158	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000333	0.00158	CcSEcCtD
Leflunomide—Pharyngitis—Capecitabine—colon cancer	0.000333	0.00158	CcSEcCtD
Leflunomide—Tachycardia—Fluorouracil—colon cancer	0.000333	0.00158	CcSEcCtD
Leflunomide—Hypotension—Irinotecan—colon cancer	0.000333	0.00158	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—colon cancer	0.000332	0.00214	CbGpPWpGaD
Leflunomide—Urinary tract disorder—Capecitabine—colon cancer	0.000332	0.00157	CcSEcCtD
Leflunomide—Insomnia—Vincristine—colon cancer	0.000331	0.00157	CcSEcCtD
Leflunomide—Oedema peripheral—Capecitabine—colon cancer	0.000331	0.00157	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—CTNNB1—colon cancer	0.00033	0.00213	CbGpPWpGaD
Leflunomide—Connective tissue disorder—Capecitabine—colon cancer	0.00033	0.00156	CcSEcCtD
Leflunomide—Urethral disorder—Capecitabine—colon cancer	0.000329	0.00156	CcSEcCtD
Leflunomide—Paraesthesia—Vincristine—colon cancer	0.000329	0.00156	CcSEcCtD
Leflunomide—Breast disorder—Methotrexate—colon cancer	0.000327	0.00155	CcSEcCtD
Leflunomide—Anorexia—Fluorouracil—colon cancer	0.000325	0.00154	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000325	0.00154	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—colon cancer	0.000325	0.0021	CbGpPWpGaD
Leflunomide—Insomnia—Irinotecan—colon cancer	0.000322	0.00153	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000322	0.00208	CbGpPWpGaD
Leflunomide—Paraesthesia—Irinotecan—colon cancer	0.00032	0.00151	CcSEcCtD
Leflunomide—Hypotension—Fluorouracil—colon cancer	0.000319	0.00151	CcSEcCtD
Leflunomide—Decreased appetite—Vincristine—colon cancer	0.000318	0.00151	CcSEcCtD
Leflunomide—Dyspnoea—Irinotecan—colon cancer	0.000318	0.0015	CcSEcCtD
Leflunomide—Erythema multiforme—Capecitabine—colon cancer	0.000318	0.0015	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—SRC—colon cancer	0.000316	0.00204	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Vincristine—colon cancer	0.000316	0.0015	CcSEcCtD
Leflunomide—Fatigue—Vincristine—colon cancer	0.000316	0.00149	CcSEcCtD
Leflunomide—Eye disorder—Capecitabine—colon cancer	0.000314	0.00148	CcSEcCtD
Leflunomide—Dyspepsia—Irinotecan—colon cancer	0.000314	0.00148	CcSEcCtD
Leflunomide—Pain—Vincristine—colon cancer	0.000313	0.00148	CcSEcCtD
Leflunomide—Constipation—Vincristine—colon cancer	0.000313	0.00148	CcSEcCtD
Leflunomide—Asthma—Methotrexate—colon cancer	0.000312	0.00148	CcSEcCtD
Leflunomide—Cardiac disorder—Capecitabine—colon cancer	0.000312	0.00147	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000311	0.00147	CcSEcCtD
Leflunomide—Decreased appetite—Irinotecan—colon cancer	0.00031	0.00147	CcSEcCtD
Leflunomide—Eosinophilia—Methotrexate—colon cancer	0.000309	0.00146	CcSEcCtD
Leflunomide—Insomnia—Fluorouracil—colon cancer	0.000309	0.00146	CcSEcCtD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—colon cancer	0.000308	0.00199	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—colon cancer	0.000308	0.00199	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000308	0.00146	CcSEcCtD
Leflunomide—Fatigue—Irinotecan—colon cancer	0.000307	0.00145	CcSEcCtD
Leflunomide—Paraesthesia—Fluorouracil—colon cancer	0.000307	0.00145	CcSEcCtD
Leflunomide—Pancreatitis—Methotrexate—colon cancer	0.000306	0.00145	CcSEcCtD
Leflunomide—Constipation—Irinotecan—colon cancer	0.000305	0.00144	CcSEcCtD
Leflunomide—Pain—Irinotecan—colon cancer	0.000305	0.00144	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—colon cancer	0.000304	0.00197	CbGpPWpGaD
Leflunomide—Dyspnoea—Fluorouracil—colon cancer	0.000304	0.00144	CcSEcCtD
Leflunomide—Immune system disorder—Capecitabine—colon cancer	0.000303	0.00144	CcSEcCtD
Leflunomide—Mediastinal disorder—Capecitabine—colon cancer	0.000303	0.00143	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—colon cancer	0.000302	0.00195	CbGpPWpGaD
Leflunomide—Chills—Capecitabine—colon cancer	0.000301	0.00143	CcSEcCtD
Leflunomide—Dyspepsia—Fluorouracil—colon cancer	0.000301	0.00142	CcSEcCtD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—colon cancer	0.0003	0.00194	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—colon cancer	0.0003	0.00194	CbGpPWpGaD
Leflunomide—Arrhythmia—Capecitabine—colon cancer	0.0003	0.00142	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—CTNNB1—colon cancer	0.0003	0.00193	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Vincristine—colon cancer	0.000299	0.00142	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—SRC—colon cancer	0.000299	0.00193	CbGpPWpGaD
Leflunomide—Decreased appetite—Fluorouracil—colon cancer	0.000297	0.0014	CcSEcCtD
Leflunomide—Alopecia—Capecitabine—colon cancer	0.000297	0.0014	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—colon cancer	0.000297	0.00192	CbGpPWpGaD
Leflunomide—Pancytopenia—Methotrexate—colon cancer	0.000297	0.0014	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000295	0.00139	CcSEcCtD
Leflunomide—Mental disorder—Capecitabine—colon cancer	0.000294	0.00139	CcSEcCtD
Leflunomide—Feeling abnormal—Irinotecan—colon cancer	0.000294	0.00139	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—colon cancer	0.000293	0.00189	CbGpPWpGaD
Leflunomide—Malnutrition—Capecitabine—colon cancer	0.000292	0.00138	CcSEcCtD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000292	0.00189	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PIK3CA—colon cancer	0.000292	0.00189	CbGpPWpGaD
Leflunomide—Dysuria—Methotrexate—colon cancer	0.000292	0.00138	CcSEcCtD
Leflunomide—Neutropenia—Methotrexate—colon cancer	0.000292	0.00138	CcSEcCtD
Leflunomide—Pain—Fluorouracil—colon cancer	0.000292	0.00138	CcSEcCtD
Leflunomide—Gastrointestinal pain—Irinotecan—colon cancer	0.000292	0.00138	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—colon cancer	0.000291	0.00188	CbGpPWpGaD
Leflunomide—Upper respiratory tract infection—Methotrexate—colon cancer	0.00029	0.00137	CcSEcCtD
Leflunomide—Body temperature increased—Vincristine—colon cancer	0.000289	0.00137	CcSEcCtD
Leflunomide—Abdominal pain—Vincristine—colon cancer	0.000289	0.00137	CcSEcCtD
Leflunomide—Flatulence—Capecitabine—colon cancer	0.000288	0.00136	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—colon cancer	0.000287	0.00186	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—colon cancer	0.000286	0.00185	CbGpPWpGaD
Leflunomide—Dysgeusia—Capecitabine—colon cancer	0.000286	0.00135	CcSEcCtD
Leflunomide—Back pain—Capecitabine—colon cancer	0.000283	0.00134	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—colon cancer	0.000283	0.00183	CbGpPWpGaD
Leflunomide—Body temperature increased—Irinotecan—colon cancer	0.000282	0.00133	CcSEcCtD
Leflunomide—Abdominal pain—Irinotecan—colon cancer	0.000282	0.00133	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—DLC1—colon cancer	0.000281	0.00182	CbGpPWpGaD
Leflunomide—Feeling abnormal—Fluorouracil—colon cancer	0.000281	0.00133	CcSEcCtD
Leflunomide—Muscle spasms—Capecitabine—colon cancer	0.000281	0.00133	CcSEcCtD
Leflunomide—Pneumonia—Methotrexate—colon cancer	0.00028	0.00133	CcSEcCtD
Leflunomide—Infestation NOS—Methotrexate—colon cancer	0.000278	0.00132	CcSEcCtD
Leflunomide—Infestation—Methotrexate—colon cancer	0.000278	0.00132	CcSEcCtD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	0.000277	0.00179	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000276	0.00131	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—colon cancer	0.000276	0.00178	CbGpPWpGaD
Leflunomide—Vision blurred—Capecitabine—colon cancer	0.000276	0.0013	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—colon cancer	0.000274	0.0013	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000272	0.00176	CbGpPWpGaD
Leflunomide—Stomatitis—Methotrexate—colon cancer	0.000271	0.00128	CcSEcCtD
Leflunomide—Ill-defined disorder—Capecitabine—colon cancer	0.000271	0.00128	CcSEcCtD
Leflunomide—Urticaria—Fluorouracil—colon cancer	0.000271	0.00128	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—SRC—colon cancer	0.000271	0.00175	CbGpPWpGaD
Leflunomide—Conjunctivitis—Methotrexate—colon cancer	0.000271	0.00128	CcSEcCtD
Leflunomide—Anaemia—Capecitabine—colon cancer	0.00027	0.00128	CcSEcCtD
Leflunomide—Body temperature increased—Fluorouracil—colon cancer	0.00027	0.00128	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—colon cancer	0.00027	0.00128	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000267	0.00172	CbGpPWpGaD
Leflunomide—Haematuria—Methotrexate—colon cancer	0.000266	0.00126	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—LGR5—colon cancer	0.000265	0.00171	CbGpPWpGaD
Leflunomide—Malaise—Capecitabine—colon cancer	0.000264	0.00125	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—colon cancer	0.000263	0.00125	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—colon cancer	0.000263	0.00124	CcSEcCtD
Leflunomide—Vertigo—Capecitabine—colon cancer	0.000263	0.00124	CcSEcCtD
Leflunomide—Hypersensitivity—Irinotecan—colon cancer	0.000263	0.00124	CcSEcCtD
Leflunomide—Asthenia—Vincristine—colon cancer	0.000263	0.00124	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—colon cancer	0.000262	0.00169	CbGpPWpGaD
Leflunomide—Leukopenia—Capecitabine—colon cancer	0.000262	0.00124	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—colon cancer	0.00026	0.00168	CbGpPWpGaD
Leflunomide—Agranulocytosis—Methotrexate—colon cancer	0.00026	0.00123	CcSEcCtD
Leflunomide—Palpitations—Capecitabine—colon cancer	0.000258	0.00122	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—colon cancer	0.000256	0.00165	CbGpPWpGaD
Leflunomide—Asthenia—Irinotecan—colon cancer	0.000256	0.00121	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—colon cancer	0.000256	0.00165	CbGpPWpGaD
Leflunomide—Cough—Capecitabine—colon cancer	0.000255	0.00121	CcSEcCtD
Leflunomide—Hypertension—Capecitabine—colon cancer	0.000252	0.00119	CcSEcCtD
Leflunomide—Hypersensitivity—Fluorouracil—colon cancer	0.000252	0.00119	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—colon cancer	0.000251	0.00119	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—colon cancer	0.00025	0.00118	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—colon cancer	0.00025	0.00118	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—colon cancer	0.00025	0.00118	CcSEcCtD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.00025	0.00161	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SRC—colon cancer	0.00025	0.00161	CbGpPWpGaD
Leflunomide—Chest pain—Capecitabine—colon cancer	0.000249	0.00118	CcSEcCtD
Leflunomide—Arthralgia—Capecitabine—colon cancer	0.000249	0.00118	CcSEcCtD
Leflunomide—Myalgia—Capecitabine—colon cancer	0.000249	0.00118	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—colon cancer	0.000248	0.00117	CcSEcCtD
Leflunomide—Anxiety—Capecitabine—colon cancer	0.000248	0.00117	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—colon cancer	0.000247	0.0016	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000247	0.00117	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—colon cancer	0.000247	0.00117	CcSEcCtD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	0.000246	0.00159	CbGpPWpGaD
Leflunomide—Discomfort—Capecitabine—colon cancer	0.000246	0.00116	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—colon cancer	0.000245	0.00116	CcSEcCtD
Leflunomide—Diarrhoea—Irinotecan—colon cancer	0.000244	0.00115	CcSEcCtD
Leflunomide—Dry mouth—Capecitabine—colon cancer	0.000243	0.00115	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CA7—colon cancer	0.000243	0.00157	CbGpPWpGaD
Leflunomide—Dizziness—Vincristine—colon cancer	0.000242	0.00115	CcSEcCtD
Leflunomide—Pruritus—Fluorouracil—colon cancer	0.000242	0.00114	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—colon cancer	0.000241	0.00155	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ABCB1—colon cancer	0.00024	0.00155	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—colon cancer	0.000239	0.00154	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—colon cancer	0.000239	0.00154	CbGpPWpGaD
Leflunomide—Infection—Capecitabine—colon cancer	0.000237	0.00112	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—colon cancer	0.000236	0.00112	CcSEcCtD
Leflunomide—DHODH—Metabolism—TYMS—colon cancer	0.000236	0.00152	CbGpPWpGaD
Leflunomide—Dizziness—Irinotecan—colon cancer	0.000236	0.00112	CcSEcCtD
Leflunomide—Nervous system disorder—Capecitabine—colon cancer	0.000234	0.00111	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—colon cancer	0.000234	0.00111	CcSEcCtD
Leflunomide—Diarrhoea—Fluorouracil—colon cancer	0.000234	0.00111	CcSEcCtD
Leflunomide—Thrombocytopenia—Capecitabine—colon cancer	0.000234	0.00111	CcSEcCtD
Leflunomide—Tachycardia—Capecitabine—colon cancer	0.000233	0.0011	CcSEcCtD
Leflunomide—Vomiting—Vincristine—colon cancer	0.000233	0.0011	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—colon cancer	0.000232	0.0011	CcSEcCtD
Leflunomide—Skin disorder—Capecitabine—colon cancer	0.000232	0.0011	CcSEcCtD
Leflunomide—Rash—Vincristine—colon cancer	0.000231	0.00109	CcSEcCtD
Leflunomide—Hyperhidrosis—Capecitabine—colon cancer	0.000231	0.00109	CcSEcCtD
Leflunomide—Dermatitis—Vincristine—colon cancer	0.000231	0.00109	CcSEcCtD
Leflunomide—Headache—Vincristine—colon cancer	0.000229	0.00108	CcSEcCtD
Leflunomide—Anorexia—Capecitabine—colon cancer	0.000227	0.00108	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—colon cancer	0.000227	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—SRC—colon cancer	0.000227	0.00147	CbGpPWpGaD
Leflunomide—Vomiting—Irinotecan—colon cancer	0.000227	0.00107	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—colon cancer	0.000226	0.00146	CbGpPWpGaD
Leflunomide—Immune system disorder—Methotrexate—colon cancer	0.000226	0.00107	CcSEcCtD
Leflunomide—Dizziness—Fluorouracil—colon cancer	0.000226	0.00107	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—colon cancer	0.000225	0.00107	CcSEcCtD
Leflunomide—Rash—Irinotecan—colon cancer	0.000225	0.00106	CcSEcCtD
Leflunomide—Dermatitis—Irinotecan—colon cancer	0.000225	0.00106	CcSEcCtD
Leflunomide—Chills—Methotrexate—colon cancer	0.000224	0.00106	CcSEcCtD
Leflunomide—Headache—Irinotecan—colon cancer	0.000223	0.00106	CcSEcCtD
Leflunomide—Hypotension—Capecitabine—colon cancer	0.000223	0.00105	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—colon cancer	0.000223	0.00144	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000223	0.00144	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—colon cancer	0.000221	0.00143	CbGpPWpGaD
Leflunomide—Alopecia—Methotrexate—colon cancer	0.000221	0.00105	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—colon cancer	0.000219	0.00104	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—colon cancer	0.000218	0.00103	CcSEcCtD
Leflunomide—Nausea—Vincristine—colon cancer	0.000217	0.00103	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000217	0.00103	CcSEcCtD
Leflunomide—Vomiting—Fluorouracil—colon cancer	0.000217	0.00103	CcSEcCtD
Leflunomide—Insomnia—Capecitabine—colon cancer	0.000216	0.00102	CcSEcCtD
Leflunomide—Rash—Fluorouracil—colon cancer	0.000215	0.00102	CcSEcCtD
Leflunomide—Dermatitis—Fluorouracil—colon cancer	0.000215	0.00102	CcSEcCtD
Leflunomide—Paraesthesia—Capecitabine—colon cancer	0.000214	0.00101	CcSEcCtD
Leflunomide—Headache—Fluorouracil—colon cancer	0.000214	0.00101	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—colon cancer	0.000213	0.00101	CcSEcCtD
Leflunomide—Dyspnoea—Capecitabine—colon cancer	0.000213	0.00101	CcSEcCtD
Leflunomide—Nausea—Irinotecan—colon cancer	0.000212	0.001	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000211	0.00136	CbGpPWpGaD
Leflunomide—Back pain—Methotrexate—colon cancer	0.000211	0.000996	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—colon cancer	0.00021	0.00136	CbGpPWpGaD
Leflunomide—Dyspepsia—Capecitabine—colon cancer	0.00021	0.000994	CcSEcCtD
Leflunomide—Decreased appetite—Capecitabine—colon cancer	0.000207	0.000981	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—colon cancer	0.000206	0.00133	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000206	0.000975	CcSEcCtD
Leflunomide—Fatigue—Capecitabine—colon cancer	0.000206	0.000973	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—colon cancer	0.000205	0.00097	CcSEcCtD
Leflunomide—Constipation—Capecitabine—colon cancer	0.000204	0.000965	CcSEcCtD
Leflunomide—Pain—Capecitabine—colon cancer	0.000204	0.000965	CcSEcCtD
Leflunomide—Nausea—Fluorouracil—colon cancer	0.000203	0.000959	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—colon cancer	0.000202	0.000955	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—colon cancer	0.000201	0.000952	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—colon cancer	0.000199	0.00129	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—colon cancer	0.000197	0.00127	CbGpPWpGaD
Leflunomide—Feeling abnormal—Capecitabine—colon cancer	0.000197	0.00093	CcSEcCtD
Leflunomide—Malaise—Methotrexate—colon cancer	0.000196	0.000929	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—colon cancer	0.000196	0.000925	CcSEcCtD
Leflunomide—Gastrointestinal pain—Capecitabine—colon cancer	0.000195	0.000923	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—colon cancer	0.000195	0.000922	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AXIN2—colon cancer	0.00019	0.00123	CbGpPWpGaD
Leflunomide—Cough—Methotrexate—colon cancer	0.00019	0.000898	CcSEcCtD
Leflunomide—Urticaria—Capecitabine—colon cancer	0.00019	0.000897	CcSEcCtD
Leflunomide—PTK2B—Immune System—BCL10—colon cancer	0.000189	0.00122	CbGpPWpGaD
Leflunomide—Abdominal pain—Capecitabine—colon cancer	0.000189	0.000892	CcSEcCtD
Leflunomide—Body temperature increased—Capecitabine—colon cancer	0.000189	0.000892	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—colon cancer	0.000188	0.00121	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—colon cancer	0.000186	0.0012	CbGpPWpGaD
Leflunomide—Myalgia—Methotrexate—colon cancer	0.000185	0.000877	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—colon cancer	0.000185	0.000877	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—colon cancer	0.000185	0.000877	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000184	0.000871	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—colon cancer	0.000183	0.000866	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—colon cancer	0.000178	0.00084	CcSEcCtD
Leflunomide—Infection—Methotrexate—colon cancer	0.000176	0.000835	CcSEcCtD
Leflunomide—Hypersensitivity—Capecitabine—colon cancer	0.000176	0.000832	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—colon cancer	0.000176	0.00113	CbGpPWpGaD
Leflunomide—Nervous system disorder—Methotrexate—colon cancer	0.000174	0.000824	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—colon cancer	0.000174	0.000823	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—colon cancer	0.000173	0.000816	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—colon cancer	0.000172	0.000812	CcSEcCtD
Leflunomide—Asthenia—Capecitabine—colon cancer	0.000171	0.00081	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—colon cancer	0.000169	0.000801	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	0.000169	0.00109	CbGpPWpGaD
Leflunomide—Pruritus—Capecitabine—colon cancer	0.000169	0.000799	CcSEcCtD
Leflunomide—DHODH—Metabolism—PPARG—colon cancer	0.000167	0.00108	CbGpPWpGaD
Leflunomide—Hypotension—Methotrexate—colon cancer	0.000166	0.000785	CcSEcCtD
Leflunomide—Diarrhoea—Capecitabine—colon cancer	0.000163	0.000772	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000162	0.000766	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—colon cancer	0.000161	0.00076	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—colon cancer	0.00016	0.00103	CbGpPWpGaD
Leflunomide—Paraesthesia—Methotrexate—colon cancer	0.000159	0.000755	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—colon cancer	0.000158	0.000749	CcSEcCtD
Leflunomide—Dizziness—Capecitabine—colon cancer	0.000158	0.000746	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—colon cancer	0.000156	0.00074	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—colon cancer	0.000155	0.001	CbGpPWpGaD
Leflunomide—Decreased appetite—Methotrexate—colon cancer	0.000154	0.00073	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.000154	0.000996	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000153	0.000725	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—colon cancer	0.000153	0.000724	CcSEcCtD
Leflunomide—Pain—Methotrexate—colon cancer	0.000152	0.000719	CcSEcCtD
Leflunomide—Vomiting—Capecitabine—colon cancer	0.000152	0.000718	CcSEcCtD
Leflunomide—Rash—Capecitabine—colon cancer	0.00015	0.000712	CcSEcCtD
Leflunomide—Dermatitis—Capecitabine—colon cancer	0.00015	0.000711	CcSEcCtD
Leflunomide—Headache—Capecitabine—colon cancer	0.000149	0.000707	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CHST5—colon cancer	0.000147	0.00095	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ODC1—colon cancer	0.000147	0.00095	CbGpPWpGaD
Leflunomide—Feeling abnormal—Methotrexate—colon cancer	0.000146	0.000692	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—colon cancer	0.000145	0.000687	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	0.000144	0.000932	CbGpPWpGaD
Leflunomide—Nausea—Capecitabine—colon cancer	0.000142	0.00067	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—colon cancer	0.000141	0.000911	CbGpPWpGaD
Leflunomide—Urticaria—Methotrexate—colon cancer	0.000141	0.000668	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—colon cancer	0.000141	0.000911	CbGpPWpGaD
Leflunomide—Body temperature increased—Methotrexate—colon cancer	0.00014	0.000664	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—colon cancer	0.00014	0.000664	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000135	0.000871	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	0.000135	0.000869	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—colon cancer	0.000132	0.00085	CbGpPWpGaD
Leflunomide—Hypersensitivity—Methotrexate—colon cancer	0.000131	0.000619	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000128	0.000829	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000128	0.000829	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—colon cancer	0.000127	0.000603	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—colon cancer	0.000126	0.000595	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000125	0.000806	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000125	0.000806	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA7—colon cancer	0.000123	0.000792	CbGpPWpGaD
Leflunomide—Diarrhoea—Methotrexate—colon cancer	0.000122	0.000575	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000121	0.000785	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—colon cancer	0.000121	0.000784	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.00012	0.000775	CbGpPWpGaD
Leflunomide—Dizziness—Methotrexate—colon cancer	0.000117	0.000556	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—colon cancer	0.000113	0.000534	CcSEcCtD
Leflunomide—Rash—Methotrexate—colon cancer	0.000112	0.00053	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—colon cancer	0.000112	0.000529	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000112	0.000722	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000112	0.00072	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—colon cancer	0.000111	0.00072	CbGpPWpGaD
Leflunomide—Headache—Methotrexate—colon cancer	0.000111	0.000526	CcSEcCtD
Leflunomide—DHODH—Metabolism—EP300—colon cancer	0.000109	0.000707	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000109	0.000706	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000109	0.000706	CbGpPWpGaD
Leflunomide—Nausea—Methotrexate—colon cancer	0.000105	0.000499	CcSEcCtD
Leflunomide—CYP1A2—Metabolism—CA7—colon cancer	0.000105	0.000677	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—colon cancer	0.000104	0.000671	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000103	0.000667	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—colon cancer	0.000103	0.000666	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2L1—colon cancer	8.88e-05	0.000574	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	8.78e-05	0.000567	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGFR3—colon cancer	8.49e-05	0.000548	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	8.3e-05	0.000536	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—colon cancer	8.09e-05	0.000523	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ODC1—colon cancer	7.43e-05	0.00048	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CHST5—colon cancer	7.43e-05	0.00048	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—colon cancer	7.17e-05	0.000463	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—colon cancer	6.61e-05	0.000427	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ODC1—colon cancer	6.35e-05	0.00041	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CHST5—colon cancer	6.35e-05	0.00041	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR3—colon cancer	5.49e-05	0.000355	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—colon cancer	5.3e-05	0.000342	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—colon cancer	5.17e-05	0.000334	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—colon cancer	5.04e-05	0.000326	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—colon cancer	4.92e-05	0.000318	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—colon cancer	4.79e-05	0.000309	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—colon cancer	4.74e-05	0.000306	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—colon cancer	4.61e-05	0.000297	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—colon cancer	4.2e-05	0.000271	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—colon cancer	3.96e-05	0.000256	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—colon cancer	3.89e-05	0.000251	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—colon cancer	3.82e-05	0.000247	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—colon cancer	3.64e-05	0.000235	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—colon cancer	3.55e-05	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—colon cancer	3.46e-05	0.000223	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—colon cancer	3.42e-05	0.000221	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—colon cancer	3.37e-05	0.000218	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—colon cancer	3.35e-05	0.000216	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—colon cancer	3.18e-05	0.000206	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—colon cancer	3.1e-05	0.0002	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.07e-05	0.000198	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—colon cancer	3.01e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—colon cancer	2.98e-05	0.000192	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—colon cancer	2.97e-05	0.000192	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—colon cancer	2.77e-05	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—colon cancer	2.77e-05	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—colon cancer	2.71e-05	0.000175	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—colon cancer	2.7e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.62e-05	0.000169	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—colon cancer	2.56e-05	0.000166	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.41e-05	0.000156	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—colon cancer	2.35e-05	0.000152	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—colon cancer	2.28e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—colon cancer	2.18e-05	0.000141	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—colon cancer	2.13e-05	0.000137	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.06e-05	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.01e-05	0.00013	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—colon cancer	1.96e-05	0.000127	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—colon cancer	1.93e-05	0.000125	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—colon cancer	1.92e-05	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—colon cancer	1.77e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.72e-05	0.000111	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—colon cancer	1.68e-05	0.000108	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—colon cancer	1.65e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.48e-05	9.59e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—colon cancer	1.37e-05	8.82e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—colon cancer	1.31e-05	8.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.27e-05	8.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—colon cancer	1.17e-05	7.54e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—colon cancer	1.07e-05	6.94e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—colon cancer	1.07e-05	6.91e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—colon cancer	9.18e-06	5.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—colon cancer	8.94e-06	5.77e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—colon cancer	7.64e-06	4.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—colon cancer	6.61e-06	4.27e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—colon cancer	5.65e-06	3.65e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—colon cancer	5.4e-06	3.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—colon cancer	4.62e-06	2.98e-05	CbGpPWpGaD
